Guo et al. compared patients with CD90-positive HCC and those with CD90-negative HCC and found that the overall survival rates at one, two and three years were 87.5% vs. 100%, 72.9% vs. 94.1% and 54.7% vs. 88.2%, respectively [12]. Here, THY1 is linked to hepatocellular carcinoma.